Pretreatment Diffusion-Weighted Imaging Lesion Volume Predicts Favorable Outcome After Intravenous Thrombolysis With Tissue-Type Plasminogen Activator in Acute Ischemic Stroke

Anna Krüetzelmann, MD; Martin Köhrmann, MD; Jan Sobesky, MD; Bastian Cheng, MD; Michael Rosenkranz, MD; Joachim Röther, MD; Peter D. Schellinger, MD; Peter Ringleb, MD; Christian Gerloff, MD; Jens Fiehler, MD; Götz Thomalla, MD

Background and Purpose—Stroke magnetic resonance imaging with perfusion and diffusion weighting has shown its potential to select patients likely to benefit from intravenous thrombolysis with tissue-type plasminogen activator (IV-tPA). We aimed to determine the predictors of favorable outcome in magnetic resonance imaging–selected, acute stroke patients treated with IV-tPA.

Methods—We analyzed the data of acute ischemic stroke patients from a prospective, multicenter, observational study of magnetic resonance imaging–based IV-tPA treatment initiated ≤6 hours from symptom onset. Neurologic deficit on admission was assessed by the National Institutes of Health Stroke Scale. Clinical outcome was assessed after 90 days according to the modified Rankin Scale. Favorable outcome was defined as a modified Rankin Scale score of 0 to 1. Patients were compared regarding baseline parameters. Multivariate regression analysis was used to identify predictors of favorable outcome.

Results—Of 174 patients, 83 (48%) reached a favorable outcome. They were younger (median age, 62 versus 67 years; \( P = 0.001 \)), had a lower National Institutes of Health Stroke Scale score on admission (median, 11 versus 15; \( P < 0.001 \)), and had smaller diffusion-weighted imaging lesions (median, 12.9 versus 20 mL; \( P = 0.001 \)). Perfusion-weighted imaging lesion volumes and onset-to-treatment time were comparable between the groups. Age \( (P = 0.017) \), National Institutes of Health Stroke Scale score on admission \( (P < 0.001) \), and diffusion-weighted imaging lesion volume \( (P = 0.047) \) were identified as independent predictors of favorable outcome.

Conclusions—A lower age, lower National Institutes of Health Stroke Scale score on admission, and smaller pretreatment diffusion-weighted imaging lesion volume were found to be associated with a favorable outcome after treatment with IV-tPA. Pretreatment perfusion lesion volume and onset-to-treatment time were not associated with outcome when patients were selected for IV-tPA by magnetic resonance imaging within 6 hours of symptom onset. (Stroke. 2011;42:00-00.)

Key Words: stroke, acute \( \text{■} \) outcome \( \text{■} \) thrombolytic therapy \( \text{■} \) tissue plasminogen activator \( \text{■} \) MRI, diffusion weighted

Thrombolytic therapy with intravenous, recombinant, tissue-type plasminogen activator (IV-tPA) improves clinical outcome after ischemic stroke.\(^1\) Magnetic resonance imaging (MRI) with perfusion- (PWI) and diffusion-weighted-imaging (DWI) is assumed to enable identification of the tissue at risk of infarction and has been suggested to be used to identify patients likely to benefit from IV-tPA treatment, even within an extended time window.\(^2\) Recently, secondary analyses of the Diffusion and Perfusion Imaging Evaluation for Understanding Stroke study\(^3\) and the Echoplanar Imaging Thrombolytic Evaluation Trial\(^4\) have brought further insights regarding the potential of MRI to guide patient selection and to predict clinical outcome after IV-tPA. Large DWI lesion volumes as well as large and severe PWI lesions were associated with symptomatic intracerebral hemorrhage\(^3\) and poor outcome,\(^3,4\) and the exclusion of patients with very large DWI lesion volumes resulted in a significant benefit of IV-tPA treatment in the Echoplanar Imaging Thrombolytic Evaluation Trial data set, which was not the case for the whole sample.\(^5\)

Received August 18, 2010; accepted November 24, 2010.
From the Klinik und Poliklinik für Neurologie (A.K., B.C., M.R., C.G., G.T.), Universitätsklinikum Hamburg-Eppendorf, Hamburg; Neurologische Klinik (M.K., P.R.), Universitätsklinikum Heidelberg, Heidelberg; Klinik für Neurologie (J.S.), Charité-Universitätsmedizin Berlin, Berlin; Neurologische Klinik (J.R.), Asklepios Klinik Altona, Hamburg; Neurologische Klinik (P.D.S.), Johannes Wesling Klinikum Minden, Minden; and Klinik und Poliklinik für Neuroradiologische Diagnostik und Intervention (J.F.), Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany.
Correspondence to Anna Christina Krüetzelmann, Kopf- und Neurozentrum, Klinik und Poliklinik für Neurologie, Universitätsklinikum Hamburg-Eppendorf, Martinistrasse 52, D-20246 Hamburg, Germany. E-mail akruetzelmann@uke.uni-hamburg.de

© 2011 American Heart Association, Inc.

Stroke is available at http://stroke.ahajournals.org

DOI: 10.1161/STROKEAHA.110.600148
We aimed to determine whether pretreatment DWI and PWI lesion volumes were associated with outcome in a large case series of patients treated with IV-tPA whose selection for such treatment was based on MRI criteria within 6 hours of symptom onset.

Methods

Patients and Treatment Protocol
We retrospectively analyzed data of acute ischemic stroke patients from a prospective, multicenter, observational study of MRI-based (including PWI and DWI) IV-tPA treatment within 6 hours from symptom onset. For those presenting within 3 hours, patients with acute ischemic stroke were treated with IV-tPA according to approved tPA protocols. For those presenting within 3 to 6 hours, treatment with IV-tPA was performed on an individual basis according to MRI findings (for a detailed description, see the original study).

MRI Protocol and Postprocessing
All MRI studies were performed on 1.5-T clinical whole-body scanners with echoplanar capabilities. The MRI protocol included an axial DWI sequence, a PWI sequence, time-of-flight MR angiography of the intracranial arteries, a T2-weighted sequence, and a T2*-weighted sequence for the exclusion of intracranial hemorrhage, as described previously in detail.

DWI and PWI lesion volumes were calculated at the participating centers by investigators who used locally established software that combined manual delineation and application of predefined thresholds of the apparent diffusion coefficient and maps of the time to peak or mean transit time.

Clinical Assessment and End Points
Severity of neurologic deficit on admission was assessed by the National Institutes of Health Stroke Scale (NIHSS).

Clinical outcome was assessed after 90 days according to the modified Rankin Scale (YI), used to determine thresholds for the prediction of favorable outcome: age, NIHSS score on admission, and DWI lesion volume as independent predictors of a favorable outcome (Table 2). In contrast, mortality was predicted by age only, and a poor outcome was predicted by DWI lesion volume and NIHSS score on admission (Table 2). Receiver operating characteristic analysis identified the following thresholds for the optimal prediction of favorable outcome: age < 63 years (area under the curve = 0.651, YI = 0.248), NIHSS score on admission < 13 (area under the curve = 0.739, YI = 0.364), and DWI lesion volume < 16 mL (area under the curve = 0.649, YI = 0.238). The optimal cutoff for the prediction of poor outcome was a DWI lesion volume of > 17.5 mL (YI = 0.244). Sensitivity, specificity, and odds ratios for these

Results

We included 174 patients with acute middle cerebral artery stroke examined by MRI and treated with IV-tPA within 6 hours from symptom onset. Of these, 83 (48%) reached a favorable outcome. Patients with a favorable outcome were younger, had a lower NIHSS score on admission, and had smaller, acute DWI lesions than did patients with an unfavorable outcome, whereas PWI lesion volumes were comparable (Table 1). Multiple-regression analysis identified age, NIHSS score on admission, and DWI lesion volume as independent predictors of a favorable outcome (Table 2). In contrast, mortality was predicted by age only, and a poor

| Table 1. Group Comparison (Favorable Versus Unfavorable Outcome) |
|-------------------------|-------------------------|-------------------------|
| Unfavorable Outcome (n=91) | Favorable Outcome (n=83) | *P* |
| Age, median (IQR), years | 67 (61–75) | 62 (54–69) | 0.001* |
| Female, no. (%) | 42 (46.2) | 23 (27.7) | 0.122† |
| Side of infarction on left, no. (%) | 58 (63.7) | 60 (72.3) | 0.327† |
| NIHSS score on admission, median (IQR), min | 15 (12–18) | 11 (7–14) | <0.001* |
| Time to tPA, median (IQR), min | 160 (125–210) | 170 (134–210) | 0.286* |
| DWI lesion volume, median (IQR), mL | 20 (10–48) | 12.9 (4–27) | 0.001* |
| PWI lesion volume, median (IQR), mL | 120 (52–216) | 99 (38–174) | 0.147* |
| SICH, no. (%) | 3 (3.3) | 1 (1.2) | 0.622† |

IQR indicates interquartile range; NIHSS, National Institutes of Health Stroke Scale; tPA, recombinant tissue-type plasminogen activator; DWI, diffusion-weighted imaging; PWI, perfusion-weighted imaging; and SICH, symptomatic intracranial haemorrhage.

| Table 2. Predictors of Favorable Outcome Compared With Mortality and Poor Outcome: Multivariate Logistic-Regression Analysis |
|-------------------------|-------------------------|-------------------------|
| Outcomes | OR | 95% CI | *P* Value |
| Favorable outcome (mRS score 0–1) | 0.962 | 0.932–0.993 | 0.017 |
| Age, per year | 0.861 | 0.792–0.935 | <0.001 |
| NIHSS score on admission, per point | 0.985 | 0.970–1.000 | 0.047 |
| DWI lesion volume, per mL | 0.981 | 0.980–1.001 | 0.010 |
| Mortality | 1.090 | 1.019–1.166 | 0.012 |
| NIHSS score on admission, per point | 1.099 | 0.980–1.213 | 0.010 |
| DWI lesion volume, per mL | 1.001 | 0.981–1.022 | 0.888 |
| Poor outcome (mRS score 4–6) | 1.102 | 1.051–1.156 | 1.102 |
| Age, per year | 1.234 | 1.108–1.375 | <0.001 |
| NIHSS score on admission, per point | 1.014 | 1.001–1.028 | 0.038 |

Results are shown for a multivariate binary regression analysis with favorable outcome, mortality, and poor outcome as the dependent variable. OR indicates odds ratio; CI, confidence interval; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; DWI, diffusion-weighted imaging.
parameters in the prediction of favorable outcome are given in Table 3.

The number of patients with a favorable outcome was clearly higher in those with an acute DWI lesion volume <16 mL (59.8% versus 37.0%, \( P = 0.004 \); see Figure 1). Dividing the sample by quartiles of DWI lesion volume showed comparable numbers of patients with a favorable outcome within the first 3 quartiles but a clearly decreased proportion of patients with a favorable outcome in the fourth quartile (patients with a DWI lesion >36 mL; see Figure 2).

To test for a potential differential effect of DWI lesion volume with regard to outcome prediction for patients treated at \( \leq 3 \) or after 3 to 6 hours, we performed an additional multivariate regression analysis including onset to treatment time \( \leq 3 \) hours or 3 to 6 hours. This analysis revealed no significant effect of onset to treatment time \( ( P = 0.288 ) \).

### Discussion

In this large sample of acute stroke patients treated with IV-tPA based on MRI criteria, lower age, less neurologic deficit on admission, and smaller DWI lesion volume predicted a favorable outcome at 90 days. The clinical predictors of favorable outcome are in line with those reported in previous studies.\(^1,9\) DWI allows the detection of acute ischemic lesions within minutes with high contrast\(^10\) and is assumed to represent mostly already irreversibly damaged tissue.\(^2\) Thus, an association between the amount of already infarcted tissue before initiation of thrombolysis appears quite straightforward. There are previous reports of MRI lesion volumes in patients treated with IV-tPA\(^5,11\); however, the numbers of IV-tPA–treated patients in those studies were small. In addition, a relation between infarct volume and long-term functional outcome after treatment with IV-tPA\(^12\) was pointed out. Of note, in our study, poor outcome, like favorable outcome, was predicted by DWI lesion volume and NIHSS score on admission, whereas mortality was predicted by age only.

In our sample, a DWI lesion volume threshold of <16 mL performed best with regard to the identification of patients likely to reach a favorable outcome. This threshold is quite similar to the result from a recently published secondary analysis of Echoplanar Imaging Thrombolytic Evaluation Trial data, which showed that the effect of IV-tPA was clearly increased in patients with acute DWI lesion volumes <18 mL, whereas no clear benefit was seen in patients with DWI lesions exceeding 25 mL.\(^5\) However, on the basis of these findings, we cannot designate a definite DWI lesion volume threshold above which thrombolysis appears to be futile or dangerous. The division of our sample by quartiles of DWI lesion volume gives the impression that only in the quartile of patients with the largest DWI lesion volumes (>36 mL) was a clearly decreased proportion of patients with favorable outcomes found. Previous reports also found that large DWI lesions were associated with poor outcomes (the so-called “malignant profile” in the Diffusion and Perfusion Imaging Evaluation for Understanding Stroke study).\(^3\) Accordingly, in the subgroup of patients with a DWI lesion >100 mL, not a single patient had a favorable outcome.

Pretreatment PWI lesion volume was not related to outcome after IV-tPA treatment. This might in large part be explained by the fact that we studied patients treated with IV-tPA. Treatment with thrombolysis is supposed to alter, via reperfusion, the fate of tissue involved in the initial PWI lesion. In line with this, PWI lesions showed a much stronger correlation with clinical outcome in patients without thrombolysis compared with patients treated with IV-tPA.\(^13\)

The outcome after IV thrombolysis is strongly associated with onset-to-treatment time in patients selected on the basis of clinical criteria and noncontrast computed tomography.\(^1\) However, in patients selected for IV-tPA based on PWI and

### Table 3. Sensitivity, Specificity, and Odds Ratios (ORs) for the Prediction of Favorable Outcome

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Sensitivity (95% CI)</th>
<th>Specificity (95% CI)</th>
<th>OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age &lt;63 years</td>
<td>0.58 (0.47–0.69)</td>
<td>0.67 (0.56–0.77)</td>
<td>2.789 (1.504–5.169)</td>
</tr>
<tr>
<td>NIHSS score on admission &lt;13</td>
<td>0.64 (0.53–0.74)</td>
<td>0.73 (0.62–0.81)</td>
<td>4.664 (2.454–8.864)</td>
</tr>
<tr>
<td>DWI lesion volume &lt;16 mL</td>
<td>0.59 (0.48–0.70)</td>
<td>0.64 (0.53–0.74)</td>
<td>2.533 (1.374–4.669)</td>
</tr>
</tbody>
</table>

CI indicates confidence interval; NIHSS, National Institutes of Health Stroke Scale; and DWI, diffusion-weighted imaging.
The proportion of patients with favorable outcomes is shown for subgroups defined by quartiles of diffusion-weighted imaging lesion volume. MRS indicates Modified Rankin Scale.

Figure 2. Proportion of patients with favorable outcomes is shown for subgroups defined by quartiles of diffusion-weighted imaging lesion volume. MRS indicates Modified Rankin Scale.

Conclusions

To summarize, our study provides further evidence from a large case series for the association of pretreatment DWI lesion volume and outcome after IV thrombolysis. Patients with small, initial DWI lesion volumes are likely to reach a favorable outcome when treated with IV-tPA, even if the PWI lesion is large. On the other hand, patients with already large DWI lesions on pretreatment MRI are less likely to reach a favorable outcome. Acute stroke MRI with PWI and DWI adds valuable information, which should be considered when thrombolysis is debated, and which may help guide treatment decisions in individual patients with acute ischemic stroke.

Disclosures

None.

References


Pretreatment Diffusion-Weighted Imaging Lesion Volume Predicts Favorable Outcome After Intravenous Thrombolysis With Tissue-Type Plasminogen Activator in Acute Ischemic Stroke

Anna Kruetzelmann, Martin Köhrmann, Jan Sobesky, Bastian Cheng, Michael Rosenkranz, Joachim Röther, Peter D. Schellinger, Peter Ringleb, Christian Gerloff, Jens Fiehler and Götz Thomalla

*Stroke,* published online March 17, 2011;
*Stroke* is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2011 American Heart Association, Inc. All rights reserved.
Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://stroke.ahajournals.org/content/early/2011/03/17/STROKEAHA.110.600148

Data Supplement (unedited) at:
http://stroke.ahajournals.org/content/suppl/2012/02/28/STROKEAHA.110.600148.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Stroke* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to *Stroke* is online at:
http://stroke.ahajournals.org//subscriptions/
Pretreatment Diffusion-Weighted Imaging Lesion Volume Predicts Favorable Outcome After Intravenous Thrombolysis With Tissue-Type Plasminogen Activator in Acute Ischemic Stroke

Anna Krueetzelmann, MD; Martin Köhrmann, MD; Jan Sobesky, MD; Bastian Cheng, MD; Michael Rosenkranz, MD; Joachim Röther, MD; Peter D. Schellinger, MD; Peter Ringleb, MD; Christian Gerloff, MD; Jens Fiehler, MD; Götz Thomalla, MD

1 Klinik und Poliklinik für Neurologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg; 2 Neurologische Klinik, Universitätsklinik Heidelberg, Heidelberg; 3 Klinik für Neurologie, Charité-Universitätsmedizin Berlin, Berlin; 4 Neurologische Klinik, Asklepios Klinik Altona, Hamburg; 5 Neurologische Klinik, Johannes Wesling Klinikum Minden, Minden; and 6 Klinik und Poliklinik für Neuroradiologische Diagnostik und Intervention, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany.

Abstract

Background and Purpose: Flow and diffusion-weighted brain magnetic resonance imaging (MRI) is a valuable tool for selecting patients who might benefit from intravenous tissue-type plasminogen activator (IV-tPA) therapy. The present study aimed to identify pretreatment predictors of a good clinical outcome in patients treated with IV-tPA for acute ischemic stroke.

Methods: Data from patients with acute ischemic stroke treated with IV-tPA within 6 hours from symptom onset were analyzed from a prospective, multicenter study. Neurological deficit was assessed at admission using the National Institutes of Health Stroke Scale (NIHSS). Clinical outcome was assessed at 90 days using modified Rankin Scale (mRS). A mRS score of 0–1 was defined as a good outcome. Baseline parameters were compared, and multivariate regression analysis was used to identify predictors of good clinical outcome.

Results: Out of 174 patients, 83 (48%) had a good clinical outcome. Patients with a good outcome were younger (median age, 62 years vs 67 years, p = 0.001), had lower NIHSS scores (median, 11 vs 15, p < 0.001), and had smaller lesions on diffusion-weighted imaging (median, 12.9 mL vs 20 mL, p = 0.001). Flow-weighted lesion volume and time from symptom onset to treatment were similar in both groups. Age (p = 0.017), NIHSS score (p < 0.001), and pretreatment diffusion-weighted lesion volume (p = 0.047) were independent predictors of good clinical outcome.

Conclusion: Younger age, lower NIHSS score, and smaller pretreatment diffusion-weighted lesion volume were independently associated with a good clinical outcome after IV-tPA treatment. Flow-weighted lesion volume and time from symptom onset to treatment were not associated with clinical outcome.

Stroke 2011; 42: 1251-1254